{"disease":{"id":"ctcl","name":"ctcl"},"drugs":{"marketed":[{"drug_id":"romidepsin","indication_name":"Cutaneous T-cell lymphoma (CTCL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Istodax","generic_name":"ROMIDEPSIN","company_name":"Teva Pharms Usa Inc","drug_phase":"marketed","molecular_target":"HDACs","drug_class":"Histone Deacetylase Inhibitor","quality_score":62,"revenue":null,"mechanism":"Romidepsin inhibits HDACs, leading to increased acetylation of histones and non-histone proteins, causing cell cycle arrest and apoptosis in cancer cells."},{"drug_id":"denileukin-diftitox-cxdl","indication_name":"Relapsed or Refractory CTCL","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"LYMPHIR","generic_name":"DENILEUKIN DIFTITOX-CXDL","company_name":"CITIUS PHARMS","drug_phase":"marketed","molecular_target":"","drug_class":"CD25-directed Cytotoxin [EPC]","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"methoxsalen","indication_name":"Palliative treatment of CTCL skin manifestations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oxsoralen-Ultra","generic_name":"METHOXSALEN","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Cytochrome P450 1A2","drug_class":"Photoactivated Radical Generator [EPC]","quality_score":65,"revenue":null,"mechanism":"Oxsoralen-Ultra works by generating free radicals when exposed to ultraviolet A (UVA) light, which helps to slow down the growth of skin cells and reduce inflammation."},{"drug_id":"89zr-zr-crefmirlimab-berdoxam","indication_name":"Plaquenil-resistant or -intolerant adult patients with cutaneous T-cell lymphoma (CTCL) who have had an inadequate response or are intolerant to at least one prior systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"[89Zr]Zr-crefmirlimab berdoxam","generic_name":"89zr-zr-crefmirlimab-berdoxam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Fibroblast Activation Protein (FAP)","drug_class":"Radiolabeled Monoclonal Antibody","quality_score":26,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01087333","title":"Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":1263,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07021495","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","phase":"","overall_status":"RECRUITING","enrollment_count":840,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT01994382","title":"Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04491825","title":"Diagnostic Classifier for Cutaneous T-cell Lymphomas","phase":"","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT05569057","title":"A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Jiangsu Simcere Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07178457","title":"Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":84,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02580552","title":"Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"miRagen Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05225584","title":"Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Kymera Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02556463","title":"A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":53,"lead_sponsor_name":"MedImmune LLC","has_results":false},{"nct_id":"NCT03239392","title":"A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Bioniz Therapeutics","has_results":false},{"nct_id":"NCT06485219","title":"A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Chengdu Zenitar Biomedical Technology Co., Ltd","has_results":false},{"nct_id":"NCT06716658","title":"JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT03240211","title":"Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"University of Virginia","has_results":false},{"nct_id":"NCT07535710","title":"Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":37,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06925464","title":"CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT07022964","title":"CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT07213882","title":"A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06914037","title":"A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT02616965","title":"A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":false},{"nct_id":"NCT05589896","title":"A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Ossium Health, Inc.","has_results":false},{"nct_id":"NCT02689453","title":"Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04362007","title":"A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Otsuka Pharmaceutical Co., Ltd.","has_results":true},{"nct_id":"NCT05879458","title":"Ritlecitinib in CTCL","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT04171791","title":"A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT05156229","title":"A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Codiak BioSciences","has_results":false},{"nct_id":"NCT01579318","title":"Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OncoSec Medical Incorporated","has_results":true},{"nct_id":"NCT04218825","title":"REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false}],"total":27},"guidelines":[],"source":"Drug Landscape verified database"}